<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055951</url>
  </required_header>
  <id_info>
    <org_study_id>VTR-045, VTR-075</org_study_id>
    <nct_id>NCT01055951</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the Solo™ Insulin Pump</brief_title>
  <official_title>Feasibility Study of the Solo™ Insulin Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medingo Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medingo Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and usability of the Solo™ insulin&#xD;
      MicroPump in subjects with type 1 diabetes who are pump users.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi center, one arm, open label and prospective study to assess the safety and&#xD;
      usability of the Solo™ MicroPump Insulin Delivery System .&#xD;
&#xD;
      The study will include a 30 days treatment period with the Solo MicroPump with no special&#xD;
      care required for maintaining glycemic control and with an optional extension period of up to&#xD;
      six month.&#xD;
&#xD;
      The study will consist of up to 5 visits and one follow up phone call one week after&#xD;
      termination of the study. In case of participating the extension period, additional visits&#xD;
      will consist once a month.&#xD;
&#xD;
      Visit 1 includes eligibility, baseline evaluation and training in handling of the Solo™&#xD;
      System. If no additional practice is required patients will be enrolled. Visit 2 will&#xD;
      commence and Solo pump will be filled with insulin. If additional practice is required&#xD;
      subject will be sent home for an additional training period of a few days practice using&#xD;
      saline and then return for visit 2.&#xD;
&#xD;
      Treatment visits will take place at 3, 14 and 30 days after the enrolment. Additional visits&#xD;
      will take place at 60, 90 and 180 days depending on the extension period.&#xD;
&#xD;
      Subjects will be asked to record blood glucose measurements, daily activities and&#xD;
      carbohydrate consumptions between visits.&#xD;
&#xD;
      Seven days after termination of study treatment a telephone contact with the study subject&#xD;
      will take place for the purpose of adverse event reporting and the completion of DTSQ&#xD;
      questionnaire.&#xD;
&#xD;
      Measurements that will be used for assessing the safety of the device are glucose levels and&#xD;
      any occurrence of AE's.&#xD;
&#xD;
      Subjects will complete DTSQ and Performance questionnaires before and at the end of the&#xD;
      treatment period for usability evaluation.&#xD;
&#xD;
      Blood and urine tests will be taken at visit 1 and 5, vital signs and physical examination&#xD;
      will be evaluated at all study visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-related adverse outcome</measure>
    <time_frame>During treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mechanical dysfunction and diabetes-related adverse outcome</measure>
    <time_frame>During treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Insulin Pump Users</condition>
  <arm_group>
    <arm_group_label>Solo MicroPump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solo MicroPump</intervention_name>
    <description>30 days treatment days with an optional extension period of up to 6 month of treatment.</description>
    <arm_group_label>Solo MicroPump</arm_group_label>
    <other_name>Solo System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range of:&#xD;
&#xD;
               -  18 to 60 years in Israel&#xD;
&#xD;
               -  16 to 60 years in Austria&#xD;
&#xD;
          -  Type I diabetes and pump treatment duration of more than 6 months.&#xD;
&#xD;
          -  Subjects who are using Humalog®, NovoRapid®, and Apidra® 100U/ml insulin&#xD;
&#xD;
          -  Measures glucose at least four times per day.&#xD;
&#xD;
          -  No more than one severe hypoglycemic or ketoacidosis episode within one year&#xD;
&#xD;
          -  Willing to sign an informed consent.&#xD;
&#xD;
          -  Cooperative, willing to attend all study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A1c &gt;= 10.0%&#xD;
&#xD;
          -  Two or more documented events of severe hypoglycemia within the previous 12 months&#xD;
&#xD;
          -  Diabetes related hospitalization over the past 12 months&#xD;
&#xD;
          -  Current significant diabetes-related complications&#xD;
&#xD;
          -  Pregnant, lactating or planning to become pregnant during the course of the study&#xD;
&#xD;
          -  Substance or alcohol abuse&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Known dermal hypersensitivity to medical adhesive&#xD;
&#xD;
          -  Recurrent episodes of skin infections or dermatological allergies&#xD;
&#xD;
          -  Serious or unstable medical or psychological conditions&#xD;
&#xD;
          -  Current participation in other clinical studies.&#xD;
&#xD;
          -  Working for a competitor company&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Gratz</city>
        <zip>A - 8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Healthcare Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>January 24, 2010</study_first_submitted>
  <study_first_submitted_qc>January 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Keren Afek</name_title>
    <organization>Medingo</organization>
  </responsible_party>
  <keyword>Insulin pumps</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

